«Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer». N. Engl. J. Med., 353, 16, 10-2005, pàg. 1673–84. DOI: 10.1056/NEJMoa052122. PMID: 16236738.
Giordano SH, Hortobagyi GN «Inflammatory breast cancer: clinical progress and the main problems that must be addressed». Breast Cancer Res., 5, 6, 2003, pàg. 284–8. DOI: 10.1186/bcr608. PMID: 14580242.Free Full Text[Enllaç no actiu].
Cavalieri E, Chakravarti D, Guttenplan J, et al «Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention». Biochim. Biophys. Acta, 1766, 1, 2006, pàg. 63–78. DOI: 10.1016/j.bbcan.2006.03.001. PMID: 16675129.
Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN «Proportion of breast cancer cases in the United States explained by well-established risk factors». J. Natl. Cancer Inst., 87, 22, 1995, pàg. 1681–5. DOI: 10.1093/jnci/87.22.1681. PMID: 7473816.
Venkitaraman, AR «cancer susceptibility and the functions of BRCA1 and BRCA2». Cell, 108, 2, 2002, pàg. 171–82. DOI: 10.1016/S0092-8674(02)00615-3.
Espey DK, Wu XC, Swan J, et al «Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives». Cancer, 110, 10, 2007, pàg. 2119–52. DOI: 10.1002/cncr.23044. PMID: 17939129.
Tammemagi CM «Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes». Curr. Opin. Obstet. Gynecol., 19, 1, 2007, pàg. 31–6. DOI: 10.1097/GCO.0b013e3280117cf8. PMID: 17218849.
Hirschman J, Whitman S, Ansell D «The black:white disparity in breast cancer mortality: the example of Chicago». Cancer Causes Control, 18, 3, 2007, pàg. 323–33. DOI: 10.1007/s10552-006-0102-y. PMID: 17285262.
Benjamin M, Reddy S, Brawley OW «Myeloma and race: a review of the literature». Cancer Metastasis Rev., 22, 1, 2003, pàg. 87–93. DOI: 10.1023/A:1022268103136. PMID: 12716040.
Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, Jatoi I «Racial disparities in breast cancer outcome: insights into host-tumor interactions». Cancer, 110, 9, 2007, pàg. 1880–8. DOI: 10.1002/cncr.22998. PMID: 17876835.
Lacroix M «Significance, detection and markers of disseminated breast cancer cells». Endocr Relat Cancer, 13, 4, 2006, pàg. 1033–67. DOI: 10.1677/ERC-06-0001. PMID: 17158753.
Philippar U, Roussos ET, Oser M, et al «A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis». Dev. Cell, 15, 6, desembre 2008, pàg. 813–28. DOI: 10.1016/j.devcel.2008.09.003. PMC: 2637261. PMID: 19081071.
«Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries». Annals of Oncology, 23, 4, 4-2012, pàg. 853–9. DOI: 10.1093/annonc/mdr352. PMID: 21821551.
«The future of cancer treatment: immunomodulation, CARs and combination immunotherapy». Nature Reviews. Clinical Oncology, 13, 5, 5-2016, pàg. 273–90. DOI: 10.1038/nrclinonc.2016.25. PMC: 5551685. PMID: 26977780.
«Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities – Systematic Review». Arquivos Brasileiros de Cardiologia, 111, 2, 8-2018, pàg. 205–212. DOI: 10.5935/abc.20180138. PMC: 6122903. PMID: 30183988.
«The Clinical Pharmacology of Anastrozole». European Oncology & Haematology, 7, 2, 2011, pàg. 106–8. DOI: 10.17925/EOH.2011.07.02.106.
«Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update». Journal of Clinical Oncology, 32, 21, 7-2014, pàg. 2255–69. DOI: 10.1200/JCO.2013.54.2258. PMC: 4876310. PMID: 24868023.
«Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials». Lancet, 386, 10001, 10-2015, pàg. 1341–1352. DOI: 10.1016/S0140-6736(15)61074-1. PMID: 26211827.
«A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer». Endocrine-Related Cancer, 18, 3, 6-2011, pàg. R79-89. DOI: 10.1530/ERC-10-0162. PMID: 21502311.
«Adjuvant trastuzumab therapy for HER2-positive breast cancer». Clinical Breast Cancer, 8, 4, 8-2008, pàg. 324–33. DOI: 10.3816/CBC.2008.n.037. PMID: 18757259.
«Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2». The New England Journal of Medicine, 344, 11, 3-2001, pàg. 783–92. DOI: 10.1056/NEJM200103153441101. PMID: 11248153.
«Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding». Clinical Cancer Research, 14, 5, 3-2008, pàg. 1325–32. DOI: 10.1158/1078-0432.CCR-07-4453. PMID: 18316551.
«Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer». N. Engl. J. Med., 353, 16, 10-2005, pàg. 1673–84. DOI: 10.1056/NEJMoa052122. PMID: 16236738.
Giordano SH, Hortobagyi GN «Inflammatory breast cancer: clinical progress and the main problems that must be addressed». Breast Cancer Res., 5, 6, 2003, pàg. 284–8. DOI: 10.1186/bcr608. PMID: 14580242.Free Full Text[Enllaç no actiu].
Cavalieri E, Chakravarti D, Guttenplan J, et al «Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention». Biochim. Biophys. Acta, 1766, 1, 2006, pàg. 63–78. DOI: 10.1016/j.bbcan.2006.03.001. PMID: 16675129.
Yager JD; Davidson NE «Estrogen carcinogenesis in breast cancer». New Engl J Med, 354, 3, 2006, pàg. 270–82. DOI: 10.1056/NEJMra050776. PMID: 16421368.
Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, i cols. «Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study (WINS)». J Natl Cancer Inst, 98, 24, pàg. 1767–1776. PMID: 17179478.
Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN «Proportion of breast cancer cases in the United States explained by well-established risk factors». J. Natl. Cancer Inst., 87, 22, 1995, pàg. 1681–5. DOI: 10.1093/jnci/87.22.1681. PMID: 7473816.
Espey DK, Wu XC, Swan J, et al «Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives». Cancer, 110, 10, 2007, pàg. 2119–52. DOI: 10.1002/cncr.23044. PMID: 17939129.
Tammemagi CM «Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes». Curr. Opin. Obstet. Gynecol., 19, 1, 2007, pàg. 31–6. DOI: 10.1097/GCO.0b013e3280117cf8. PMID: 17218849.
Hirschman J, Whitman S, Ansell D «The black:white disparity in breast cancer mortality: the example of Chicago». Cancer Causes Control, 18, 3, 2007, pàg. 323–33. DOI: 10.1007/s10552-006-0102-y. PMID: 17285262.
Benjamin M, Reddy S, Brawley OW «Myeloma and race: a review of the literature». Cancer Metastasis Rev., 22, 1, 2003, pàg. 87–93. DOI: 10.1023/A:1022268103136. PMID: 12716040.
Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, Jatoi I «Racial disparities in breast cancer outcome: insights into host-tumor interactions». Cancer, 110, 9, 2007, pàg. 1880–8. DOI: 10.1002/cncr.22998. PMID: 17876835.
Lacroix M «Significance, detection and markers of disseminated breast cancer cells». Endocr Relat Cancer, 13, 4, 2006, pàg. 1033–67. DOI: 10.1677/ERC-06-0001. PMID: 17158753.
Philippar U, Roussos ET, Oser M, et al «A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis». Dev. Cell, 15, 6, desembre 2008, pàg. 813–28. DOI: 10.1016/j.devcel.2008.09.003. PMC: 2637261. PMID: 19081071.
«Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries». Annals of Oncology, 23, 4, 4-2012, pàg. 853–9. DOI: 10.1093/annonc/mdr352. PMID: 21821551.
«The future of cancer treatment: immunomodulation, CARs and combination immunotherapy». Nature Reviews. Clinical Oncology, 13, 5, 5-2016, pàg. 273–90. DOI: 10.1038/nrclinonc.2016.25. PMC: 5551685. PMID: 26977780.
«Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities – Systematic Review». Arquivos Brasileiros de Cardiologia, 111, 2, 8-2018, pàg. 205–212. DOI: 10.5935/abc.20180138. PMC: 6122903. PMID: 30183988.
«Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update». Journal of Clinical Oncology, 32, 21, 7-2014, pàg. 2255–69. DOI: 10.1200/JCO.2013.54.2258. PMC: 4876310. PMID: 24868023.
«Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials». Lancet, 386, 10001, 10-2015, pàg. 1341–1352. DOI: 10.1016/S0140-6736(15)61074-1. PMID: 26211827.
«A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer». Endocrine-Related Cancer, 18, 3, 6-2011, pàg. R79-89. DOI: 10.1530/ERC-10-0162. PMID: 21502311.
«Adjuvant trastuzumab therapy for HER2-positive breast cancer». Clinical Breast Cancer, 8, 4, 8-2008, pàg. 324–33. DOI: 10.3816/CBC.2008.n.037. PMID: 18757259.
«Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2». The New England Journal of Medicine, 344, 11, 3-2001, pàg. 783–92. DOI: 10.1056/NEJM200103153441101. PMID: 11248153.
«Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding». Clinical Cancer Research, 14, 5, 3-2008, pàg. 1325–32. DOI: 10.1158/1078-0432.CCR-07-4453. PMID: 18316551.
Giordano SH, Hortobagyi GN «Inflammatory breast cancer: clinical progress and the main problems that must be addressed». Breast Cancer Res., 5, 6, 2003, pàg. 284–8. DOI: 10.1186/bcr608. PMID: 14580242.Free Full Text[Enllaç no actiu].
Lane-Claypon, Janet Elizabeth. A further report on cancer of the breast, with special reference to its associated antecedent conditions. London, Greater London: Her Majesty’s Stationery Office (HMSO), 1926. OCLC14713036.